Across the world, there are millions of people living with cardiovascular, renal and metabolic diseases. We’re better understanding the biology of these diseases. Targeting what drives them. Pioneering new cell and gene therapies that have the potential to regenerate vital organs.
Working with world leading academics, NGOs and industry partners. As well as healthcare professionals, policymakers and patients, to improve diagnosis, speed-up clinical trials, and get our medicines to more people faster.
By 2032, we aim to be leading the world in CVRM therapies, with as many as 15 life-changing new medicines. Developed and delivered by making the connections that empower us to fulfil our ambition, to stop - and one day - cure these diseases.